India’s rejection of Novartis’s patent is but a small step in the right direction

Commentators have lauded the decision, but the government must go much further to help the millions of ordinary Indian people indebted because of the cost of common drugs, says Soumyadeep Bhaumik

 

The ripples India created by issuing the first compulsory licence, of the patented drug sorafenib in 2012,1 are threatening to become a tidal wave now that the Supreme Court has rejected Novartis’s patent application for the β-polymorphic form of imatinib mesylate, called Glivec.2 This landmark judgment has been widely praised by health activists and international humanitarian organisations such as Médecins Sans Frontières, which depend on cheap Indian generics for supply.3

The decision has been widely portrayed as a major blow to big pharma and a boost to Indian generic drug makers. But how many people will benefit from such moves, which mostly affect expensive drugs that are aimed at patients in private healthcare?

Read the full Commentary on this issue by Dr. Soumyadeep B at the British Medical Journal 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s